CN118804748A - 固态形式的fgfr抑制剂 - Google Patents

固态形式的fgfr抑制剂 Download PDF

Info

Publication number
CN118804748A
CN118804748A CN202280091311.6A CN202280091311A CN118804748A CN 118804748 A CN118804748 A CN 118804748A CN 202280091311 A CN202280091311 A CN 202280091311A CN 118804748 A CN118804748 A CN 118804748A
Authority
CN
China
Prior art keywords
solid form
exhibits
ray powder
powder diffraction
diffraction reflections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280091311.6A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂芬·W·卡尔多
陶菲克·卡努尼
安德鲁·菲米斯特
贾亚钱德拉·P·雷迪
约翰·泰霍纳斯
夏巴汉·恰佩德
皮尔坦苏·潘迪
詹森·M·考克斯
罗伯特·卡尼亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinnaite Biopharmaceutical Co
Original Assignee
Jinnaite Biopharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinnaite Biopharmaceutical Co filed Critical Jinnaite Biopharmaceutical Co
Publication of CN118804748A publication Critical patent/CN118804748A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
CN202280091311.6A 2021-12-08 2022-12-07 固态形式的fgfr抑制剂 Pending CN118804748A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163287212P 2021-12-08 2021-12-08
US63/287,212 2021-12-08
PCT/US2022/081060 WO2023107980A1 (en) 2021-12-08 2022-12-07 Solid state forms of an fgfr inhibitor

Publications (1)

Publication Number Publication Date
CN118804748A true CN118804748A (zh) 2024-10-18

Family

ID=86731361

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280091311.6A Pending CN118804748A (zh) 2021-12-08 2022-12-07 固态形式的fgfr抑制剂

Country Status (12)

Country Link
US (1) US20250059170A1 (https=)
EP (1) EP4444302A4 (https=)
JP (1) JP2024542840A (https=)
KR (1) KR20240119095A (https=)
CN (1) CN118804748A (https=)
AU (1) AU2022407440A1 (https=)
CA (1) CA3239792A1 (https=)
CL (1) CL2024001679A1 (https=)
IL (1) IL313359A (https=)
MX (1) MX2024006933A (https=)
TW (1) TW202332432A (https=)
WO (1) WO2023107980A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11345681B1 (en) 2020-06-05 2022-05-31 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
AU2022407439A1 (en) * 2021-12-08 2024-06-27 Kinnate Biopharma Inc. Treatment of cancer with an fgfr kinase inhibitor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10124003B2 (en) * 2013-07-18 2018-11-13 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for FGFR inhibitor-resistant cancer
CN107840842A (zh) * 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用
EP3969442A4 (en) * 2019-05-17 2023-08-02 Kinnate Biopharma Inc. FIBROBLAST GROWTH FACTOR RECEPTOR KINASE INHIBITORS
US11345681B1 (en) * 2020-06-05 2022-05-31 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases

Also Published As

Publication number Publication date
TW202332432A (zh) 2023-08-16
IL313359A (en) 2024-08-01
KR20240119095A (ko) 2024-08-06
EP4444302A1 (en) 2024-10-16
WO2023107980A1 (en) 2023-06-15
AU2022407440A1 (en) 2024-06-20
CA3239792A1 (en) 2023-06-15
CL2024001679A1 (es) 2024-11-29
US20250059170A1 (en) 2025-02-20
EP4444302A4 (en) 2025-09-03
MX2024006933A (es) 2024-08-26
JP2024542840A (ja) 2024-11-15

Similar Documents

Publication Publication Date Title
CN112423844B (zh) Rad1901-2hcl的多晶型形式
RU2603138C1 (ru) Кристаллическая форма хидамида, способ ее получения и применение
CN106420743A (zh) C‑met调节剂药物组合物
CN112142679B (zh) 一种吉非替尼与香草酸共晶甲醇溶剂合物及其制备方法
JP7825636B2 (ja) （ｓ）－ｎ－（３－（２－（（（ｒ）－１－ヒドロキシプロパン－２－イル）アミノ）－６－モルホリノピリジン－４－イル）－４－メチルフェニル）－３－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびその塩の固体状態での形態
JP7802200B2 (ja) 置換のアミノ６員窒素複素環式化合物の塩及びその結晶形、製造方法と応用
CN118804748A (zh) 固态形式的fgfr抑制剂
RU2598378C2 (ru) Кристаллические формы iii и iv n-бензоилстауроспорина
CN106279126B (zh) 阿法替尼酸加成盐及其晶型、其制备方法及药物组合物
WO2019195569A1 (en) Solid-state forms of abemaciclib, their use and preparation
TWI705065B (zh) 嗎啉衍生物的鹽及其晶型、其製備方法及藥物組成物、用途
WO2023165501A1 (zh) Azd5305的晶型及其制备方法和用途
TWI922665B (zh) (s)-n-(3-(2-(((r)-1-羥基丙-2-基)胺基)-6-嗎啉基吡啶-4-基)-4-甲基苯基)-3-(2,2,2-三氟乙基)吡咯啶-1-甲醯胺及其鹽之固態形式
JP2025505141A (ja) Ｍｃｌ－１阻害剤の結晶形態
CN102093387B (zh) 4,5,6,7-四氢异噁唑并[5,4-c]吡啶-3-醇一水合物的晶型化合物
CN113943270B (zh) 一种阿昔替尼晶型
HK40107041A (zh) 固态形式的(s)-n-(3-(2-(((r)-1-羟基丙-2-基)氨基)-6-吗啉代吡啶-4-基)-4-甲基苯基)-3-(2，2，2-三氟乙基)吡咯烷-1-甲酰胺及其盐
WO2022253261A1 (zh) Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途
JP2026502614A (ja) Ｃｄｋ阻害剤およびその薬学的に許容される塩の結晶形ならびにそれらの使用
WO2024141040A1 (zh) 作为axl抑制剂的药物组合物
HK40115548A (zh) 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式
CN120383595A (zh) 抑制cdk4/6活性化合物的半l-酒石酸盐一水合物
CN115477646A (zh) 小檗碱柚皮素盐晶型及其制备方法和其组合物与应用
CN118515647A (zh) 喹啉衍生物的结晶及其制备方法
CN115490683A (zh) 小檗碱没食子酸盐晶型及其制备方法和其组合物与应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination